IL273567D0 - Derivatives of (3a,sp,7a)-3,7-dioxy-23-amino-24-norcholane as fxr/tgrs modulators - Google Patents

Derivatives of (3a,sp,7a)-3,7-dioxy-23-amino-24-norcholane as fxr/tgrs modulators

Info

Publication number
IL273567D0
IL273567D0 IL273567A IL27356720A IL273567D0 IL 273567 D0 IL273567 D0 IL 273567D0 IL 273567 A IL273567 A IL 273567A IL 27356720 A IL27356720 A IL 27356720A IL 273567 D0 IL273567 D0 IL 273567D0
Authority
IL
Israel
Prior art keywords
norcholane
tgrs
fxr
dioxy
modulators
Prior art date
Application number
IL273567A
Other languages
Hebrew (he)
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201462084769P priority Critical
Priority to US201562103374P priority
Priority to US14/951,989 priority patent/US10208081B2/en
Priority to PCT/US2015/062826 priority patent/WO2016086218A1/en
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of IL273567D0 publication Critical patent/IL273567D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
IL273567A 2014-11-26 2020-03-24 Derivatives of (3a,sp,7a)-3,7-dioxy-23-amino-24-norcholane as fxr/tgrs modulators IL273567D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US201462084769P true 2014-11-26 2014-11-26
US201562103374P true 2015-01-14 2015-01-14
US14/951,989 US10208081B2 (en) 2014-11-26 2015-11-25 Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
PCT/US2015/062826 WO2016086218A1 (en) 2014-11-26 2015-11-27 Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof

Publications (1)

Publication Number Publication Date
IL273567D0 true IL273567D0 (en) 2020-05-31

Family

ID=56075071

Family Applications (2)

Application Number Title Priority Date Filing Date
IL252449A IL252449D0 (en) 2014-11-26 2017-05-23 Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
IL273567A IL273567D0 (en) 2014-11-26 2020-03-24 Derivatives of (3a,sp,7a)-3,7-dioxy-23-amino-24-norcholane as fxr/tgrs modulators

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL252449A IL252449D0 (en) 2014-11-26 2017-05-23 Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof

Country Status (23)

Country Link
US (3) US10208081B2 (en)
EP (1) EP3223822B1 (en)
JP (1) JP2017536379A (en)
KR (1) KR20170087935A (en)
CN (1) CN107106575A (en)
AU (1) AU2015353372B2 (en)
BR (1) BR112017011126A2 (en)
CA (1) CA2968673A1 (en)
DK (1) DK3223822T3 (en)
HK (1) HK1244707A1 (en)
HR (1) HRP20201420T1 (en)
IL (2) IL252449D0 (en)
LT (1) LT3223822T (en)
MX (1) MX2017006832A (en)
PH (1) PH12017500941A1 (en)
PL (1) PL3223822T3 (en)
PT (1) PT3223822T (en)
RS (1) RS60836B1 (en)
RU (1) RU2707280C2 (en)
SG (2) SG10201909545XA (en)
SI (1) SI3223822T1 (en)
WO (1) WO2016086218A1 (en)
ZA (1) ZA201704154B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP3215179A4 (en) 2014-11-06 2018-07-25 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
WO2016079520A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
US10538550B2 (en) 2014-11-19 2020-01-21 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal FXR modulators
PT3221331T (en) 2014-11-19 2019-12-23 Nzp Uk Ltd 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
JP6724004B2 (en) 2014-11-19 2020-07-15 エヌゼットピー ユーケー リミテッド 5β-6-Alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroid FXR modulators
AU2015353473A1 (en) 2014-11-26 2017-06-08 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
RU2712099C2 (en) 2015-03-31 2020-01-24 Энанта Фармасьютикалс, Инк. Bile acid derivatives as fxr/tgr5 agonists and methods for use thereof
US10800807B2 (en) 2015-06-19 2020-10-13 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
KR20180100703A (en) * 2016-01-28 2018-09-11 치아타이 티안큉 파마수티컬 그룹 주식회사 Steroid derivatives FXR function bodies
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
CA3026512A1 (en) 2016-06-13 2017-12-21 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CA3045023A1 (en) * 2016-11-29 2018-06-07 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
JP2020508316A (en) 2017-02-21 2020-03-19 ジェンフィGenfit Combination of PPAR agonist and FXR agonist
KR20200010215A (en) 2017-04-07 2020-01-30 이난타 파마슈티칼스, 인코포레이티드 Process for preparing sulfonyl carbamate bile acid derivative
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1592791A (en) 1977-01-07 1981-07-08 Radiochemical Centre Ltd Selenium- or tellurium-containing bile acids and derivatives thereof
US4917826A (en) 1985-10-18 1990-04-17 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
IT1255449B (en) 1992-06-30 1995-10-31 Fabio Berlati Use of nor- and homo-derivatives of bile acids as drug absorption promoters.
IT1255485B (en) 1992-08-04 1995-11-06 Erregierre Ind Chim Process for preparing glycine-conjugated bile acids and related therapeutic compositions for the treatment of liver failure
TW289020B (en) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
TW289757B (en) 1993-05-08 1996-11-01 Hoechst Ag
JP3696884B2 (en) 1994-03-25 2005-09-21 アイソテクニカ、インコーポレーテッドIsotechnika Inc. Enhancement of drug efficacy by deuteration
US5646316A (en) 1994-04-08 1997-07-08 Osteoarthritis Sciences, Inc. Bile acid inhibitors of metalloproteinase enzymes
JPH1160594A (en) 1997-08-25 1999-03-02 Sankyo Co Ltd Bile acid derivative
JP3865890B2 (en) 1997-09-30 2007-01-10 富士フイルムホールディングス株式会社 Positive photosensitive composition
ES2326850T3 (en) 1998-12-23 2009-10-20 Glaxo Group Limited Tests for nuclear receptors ligandos.
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
US20020098999A1 (en) 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
US6992076B2 (en) 2000-10-06 2006-01-31 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
EP1392714B1 (en) 2001-03-12 2005-08-31 Intercept Pharmaceuticals, Inc. Steroids as agonists for fxr
AT381542T (en) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4 core receptor binding compounds
AU2003228485A1 (en) 2002-04-12 2003-10-27 The University Of Chicago Farnesoid x-activated receptor agonists
ITMI20021080A1 (en) 2002-05-21 2003-11-21 Marcello Izzo Pharmaceutical combinations for topical use based on iron chelates, metalloprotease inhibitors and factor xiii for the treatment of
JP2006515838A (en) 2002-11-22 2006-06-08 スミスクライン ビーチャム コーポレーション Farnesoid X receptor agonist
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
PT2712617T (en) 2004-03-12 2017-02-13 Intercept Pharmaceuticals Inc Treatment of fibrosis using fxr ligands
ITMI20050912A1 (en) 2005-05-19 2006-11-20 Erregierre Spa 3-a-ya (b) -dihydroxy-6-a (b) -alkyl-5b-colanic acid preparation process
JP5081161B2 (en) 2005-12-19 2012-11-21 スミスクライン ビーチャム コーポレーション Farnesoid X receptor agonist
EP1978968A2 (en) * 2006-02-01 2008-10-15 Brigham Young University Cationic steroid antimicrobial compositions for treating or preventing hiv infections
AU2007212126B2 (en) 2006-02-03 2012-07-19 Eli Lilly And Company Compounds and methods for modulating FX-receptors
WO2007095174A2 (en) 2006-02-14 2007-08-23 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
CA2681639A1 (en) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with er stress
PL2029547T3 (en) 2006-05-24 2010-09-30 Lilly Co Eli Fxr agonists
DE602007005256D1 (en) 2006-05-24 2010-04-22 Lilly Co Eli COMPOUNDS AND METHOD FOR MODULATING FX RECEPTORS
PT2040713E (en) 2006-06-27 2014-10-13 Intercept Pharmaceuticals Inc Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
JP2009543823A (en) 2006-07-17 2009-12-10 ノバルティス アクチエンゲゼルシャフト Sulfonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
CL2007003035A1 (en) 2006-10-24 2008-05-16 Smithkline Beechman Corp Substituted isoxazole derivative compounds, x-farnesoid receptor agonists; preparation procedure; pharmaceutical composition comprising it; and use of the compound in the treatment of obesity, diabetes mellitus, fibrosis in organs,
WO2008091540A2 (en) * 2007-01-19 2008-07-31 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as tgr5 modulators and methods of use thereof
EP1947108A1 (en) 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
BRPI0812521A2 (en) 2007-06-13 2015-06-23 Glaxosmithkline Llc Compound, pharmaceutical composition, method for treating disease in a mammal, process for preparing a compound, and use of a compound
EA200901662A1 (en) 2007-07-02 2010-06-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Агонисты фарнезоидного х-рецептора
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
EP3293195A1 (en) 2007-09-06 2018-03-14 OHR Pharmaceutical, Inc. Compounds for use in treating diabetes
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
AU2009276507B2 (en) 2008-07-30 2015-11-19 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
JP2012517479A (en) 2009-02-12 2012-08-02 エグゼリクシス, インコーポレイテッド Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013020108A2 (en) 2011-08-04 2013-02-07 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pancreatitis
US20130116218A1 (en) 2011-09-29 2013-05-09 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
AU2013256362A1 (en) 2012-05-01 2014-11-13 Catabasis Pharmaceuticals, Inc. Fatty acid conjugates of statin and FXR agonists: compositions and methods of use
CA3047776A1 (en) 2012-06-19 2013-12-27 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
WO2014036379A2 (en) 2012-08-31 2014-03-06 Metselex Bile acids prevent or abolish progression of parkinson's and related neurodegenerative diseases
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140206657A1 (en) 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
WO2014184271A1 (en) 2013-05-14 2014-11-20 Tes Pharma Srl. 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
JP6556129B2 (en) 2013-08-01 2019-08-07 アメリカ合衆国 Farnesoid X receptor inhibitor and pharmaceutical use
US20150112089A1 (en) 2013-10-22 2015-04-23 Metselex, Inc. Deuterated bile acids
DK3149019T3 (en) 2014-05-29 2020-02-17 Bar Pharmaceuticals S R L Cholan derivatives for use in the treatment and / or prevention of FXR- and TGR5 / GPBAR1-mediated diseases
EP3215179A4 (en) 2014-11-06 2018-07-25 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
AU2015353473A1 (en) 2014-11-26 2017-06-08 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
WO2016086134A1 (en) * 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US20160176917A1 (en) 2014-11-26 2016-06-23 Enanta Pharmaceuticals, Inc. Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
JP2018505190A (en) 2015-02-11 2018-02-22 エナンタ ファーマシューティカルズ インコーポレイテッド Bile acid analogs as FXR / TGR5 agonists and methods of use thereof
RU2712099C2 (en) 2015-03-31 2020-01-24 Энанта Фармасьютикалс, Инк. Bile acid derivatives as fxr/tgr5 agonists and methods for use thereof
JP2018519246A (en) 2015-04-28 2018-07-19 ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド Cholic acid derivative, production method thereof and pharmaceutical use
CN106083978A (en) 2015-04-28 2016-11-09 上海迪诺医药科技有限公司 Sulfonyl amino carbonyl derivant, its pharmaceutical composition and application
CN107531743B (en) 2015-04-29 2020-05-05 正大天晴药业集团股份有限公司 Chenodeoxycholic acid derivatives
MX2017016611A (en) 2015-06-19 2018-05-15 Intercept Pharmaceuticals Inc Tgr5 modulators and methods of use thereof.
MX2018001491A (en) 2015-08-07 2018-04-24 Intercept Pharmaceuticals Inc Methods for preparation of bile acids and derivatives thereof.
CN105175473B (en) 2015-08-19 2018-12-21 丽珠医药集团股份有限公司 A kind of Austria shellfish cholic acid crystal form I and preparation method thereof, pharmaceutical composition and purposes
CN106478759A (en) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 Shellfish chlolic acid derivatives difficult to understand and its production and use
CN106518946A (en) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 Sulfonylurea derivative and pharmaceutical composition and application thereof
JP2018528230A (en) 2015-09-24 2018-09-27 インターセプト ファーマシューティカルズ, インコーポレイテッド Methods and intermediates for the preparation of bile acid derivatives
EP3359160A4 (en) 2015-10-07 2019-06-05 Intercept Pharmaceuticals, Inc. Farnesoid x receptor modulators
KR20180100703A (en) 2016-01-28 2018-09-11 치아타이 티안큉 파마수티컬 그룹 주식회사 Steroid derivatives FXR function bodies
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US10815267B2 (en) 2016-03-11 2020-10-27 Intercept Pharmaceuticals, Inc. 3-desoxy derivative and pharmaceutical compositions thereof
CA3045023A1 (en) 2016-11-29 2018-06-07 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
KR20200010215A (en) 2017-04-07 2020-01-30 이난타 파마슈티칼스, 인코포레이티드 Process for preparing sulfonyl carbamate bile acid derivative

Also Published As

Publication number Publication date
US10208081B2 (en) 2019-02-19
US10696713B2 (en) 2020-06-30
LT3223822T (en) 2020-10-12
SG10201909545XA (en) 2019-11-28
RU2707280C2 (en) 2019-11-26
HRP20201420T1 (en) 2020-12-11
US20190194245A1 (en) 2019-06-27
KR20170087935A (en) 2017-07-31
WO2016086218A1 (en) 2016-06-02
HK1244707A1 (en) 2018-08-17
JP2017536379A (en) 2017-12-07
RU2017120970A (en) 2018-12-26
US20160185815A1 (en) 2016-06-30
IL252449D0 (en) 2017-07-31
RS60836B1 (en) 2020-10-30
PH12017500941A1 (en) 2017-11-20
AU2015353372A1 (en) 2017-06-15
ZA201704154B (en) 2020-03-25
SG11201704227QA (en) 2017-06-29
EP3223822B1 (en) 2020-07-01
CN107106575A (en) 2017-08-29
MX2017006832A (en) 2018-02-13
BR112017011126A2 (en) 2018-01-23
PL3223822T3 (en) 2021-01-11
DK3223822T3 (en) 2020-09-07
AU2015353372B2 (en) 2020-07-23
EP3223822A1 (en) 2017-10-04
PT3223822T (en) 2020-08-31
US20200347092A1 (en) 2020-11-05
RU2017120970A3 (en) 2018-12-26
CA2968673A1 (en) 2016-06-02
EP3223822A4 (en) 2018-07-11
SI3223822T1 (en) 2020-11-30

Similar Documents

Publication Publication Date Title
HRP20190575T1 (en) Immunomodulators
IL252853D0 (en) Immunomodulators
IL251589D0 (en) Immunomodulators
EP3212259A4 (en) E-vaping cartridge
EP3209527A4 (en) Self-conforming airbag
IL246362D0 (en) Novel glutaminase inhibitors
AP00747S1 (en) Cap for headset
IL252550D0 (en) Transdermal cannabinoid formulations
EP3171299A4 (en) Multi-smartcard
EP3195630A4 (en) Geolocation-based pictographs
SG11201607760RA (en) Device-to-device synchronization
AP00744S1 (en) Headset
HK1253304A1 (en) Phenoxymethyl derivatives
HK1244729A1 (en) Intranasal administration
IL250511D0 (en) Solid state forms of ibrutinib
IL246785D0 (en) Benzimidazol-2-amines as midh1 inhibitors
EP3189917A4 (en) Throw-away tip
IL251417D0 (en) Emulated endpoint configuration
IL277624D0 (en) Compositions for modulating c9orf72 expression
HK1256599A1 (en) Modulators of ror-gamma
HK1226398A1 (en) Benzimidazol-2-amines as midh1 inhibitors
IL259421D0 (en) Modulators of ror-gamma
IL231811D0 (en) Asymmetric multirotor helicopter
EP3099695A4 (en) Compounds
EP3228143A4 (en) Inactive communication mode